The present invention is directed to medical devices having a first porous substrate layer with at least a surface coating thereon of a first co-reactive component and a second substrate layer with at least a surface coating layer of a second co-reactive component that reacts with the first co-reactive component, and a removable barrier layer positioned between the first substrate layer and second substrate layer and in contact with said first substrate layer and said second substrate layer.

The present invention relates to a hemostatic absorbable composition, comprising: a flowable plurality of separate aggregates each comprising: a plurality of absorbable carrier particles coated on a surface thereof by a plurality of smaller particles comprising an absorbable supplemental hemostasis-promoting agent. In some embodiments, the absorbable carrier particles comprise gelatin or collagen, and the supplemental hemostasis-promoting agent comprises oxidized cellulose, oxidized regenerated cellulose, carboxylic oxidized cellulose, carboxylic oxidized regenerated cellulose, thrombin, or tranexamic acid.

The invention as described herein provides methods for treating a bone of a patient, including locating a treatment volume in a bone of the patient, administering a sclerosing agent to the treatment volume, and, after administering the sclerosing agent, administering bone graft material to the treatment volume. In some embodiments, the sclerosing agent and the bone graft are administered in a minimally invasive manner using a delivery device. The placement of the delivery device and/or the administration of the sclerosing agent and/or bone graft can use imaging to guide the placement and/or administration. The patient can be a pediatric patient and the treatment volume can comprise a bone lesion, a unicameral bone cyst or an aneurysmal bone cyst.

The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated oxidized regenerated cellulose (ORC) fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

The present disclosure provides a recombinant collagen and a recombinant collagen sponge material. The recombinant collagen comprises: (a) a protein composed of the amino acid sequence represented by SEQ ID NO: 2; and/or (b) a protein which has the same function as (a) and is derived from (a) by substitution, deletion and/or addition of one or more amino acids in SEQ ID NO:2. The recombinant collagen sponge material is obtained by sequential physical cross-linking and chemical cross-linking of the recombinant collagen. The recombinant collagen sponge material according to the present disclosure is capable of hemostasis, wound surface repair, moisture absorption and platelet aggregation, and has high moisture absorption, a significant hemostatic effect and good biocompatibility, assuming great clinical significance in the field of surgery.

A bleeding control device is provided. The device includes an elongate member with a holding portion and an application portion. A known amount of hemostatic solute within a solution is administered to the application portion and allowed to dry. The elongate member is then sterilized. The resulting bleeding control device may be used during medical procedures such as root canal procedures and others.

An embodiment includes a system comprising a thermoset polyurethane shape memory polymer (SMP) foam that includes at least one antimicrobial agent. The antimicrobial agent may include at least one phenolic acid that is a pendent group chemically bonded to a polyurethane polymer chain of the SMP foam. Other embodiments are described herein.

Delivery devices, delivery systems, and related methods, for precise administration of hemostatic compositions are disclosed, which may include a trigger mechanism, a pusher, a valve, and a cannula. The pusher is configured to engage with the trigger mechanism, retain a first syringe, a least by coupling with a plunger of the first syringe. The valve is fluidly coupled to the first syringe. The valve is further configured to engage with a second syringe, in fluid communication with both the valve and the first syringe. The cannula extends distally from and is fluidly coupled to the valve. Activation of the trigger mechanism causes the pusher and the plunger of the first syringe to translate in a distal direction, to expel a composition out of the first syringe, through the valve, through the cannula, and out of a distal end of the cannula.

Provided is a tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.